Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

Wong, Tien YTien YWongHaskova, ZdenkaZdenkaHaskovaAsik, KemalKemalAsikBaumal, Caroline RCaroline RBaumalCsaky, Karl GKarl GCsakyEter, NicoleNicoleEterIves, Jane AJane AIvesJaffe, Glenn JGlenn JJaffeKorobelnik, Jean-FrançoisJean-FrançoisKorobelnikLin, HughHughLinMurata, ToshinoriToshinoriMurataRuamviboonsuk, PaisanPaisanRuamviboonsukSchlottmann, Patricio GPatricio GSchlottmannSeres, András IAndrás ISeresSilverman, DavidDavidSilvermanSun, XiaodongXiaodongSunTang, YannanYannanTangWells, John AJohn AWellsYoon, Young HeeYoung HeeYoonWykoff, Charles CCharles CWykoffCHANG-HAO YANG et al.2024-03-292024-03-29202401616420https://scholars.lib.ntu.edu.tw/handle/123456789/641616To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.gov identifiers, NCT03622580 and NCT03622593, respectively) phase 3 trials of diabetic macular edema (DME).enAngiopoietin-2; Diabetic macular edema; Faricimab; Vascular endothelial growth factor A; Vascular stabilityFaricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trialsjournal article10.1016/j.ophtha.2023.12.026381581592-s2.0-85187381197https://api.elsevier.com/content/abstract/scopus_id/85187381197